Age-Dependent Effect of Abciximab in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Interventions
Key result
Abciximab cuts 30-day MACE ~43% in patients under 70 but lacks benefit in older patients.
- n=2,022
Why the study?
Does abciximab reduce 30-day MACE in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI, and does this effect vary by age?
Population
2022 patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary…
Comparison
Abciximab administered during a PCI procedure vs Placebo administered during a PCI procedure
Design
Cohort, randomized to receive abciximab or placebo
Follow-up
30 days
Authors
Discussion
Loading...
Member takes
Implication
Age-stratified abciximab use in NSTE-ACS PCI should not change practice; leaves open confirmation of this interaction in randomized trials.
Study Design
Type
RCT (n=2,022)
Randomization
randomized
Structured PICO
Does abciximab reduce 30-day MACE in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI, and does this effect vary by age?
P
Population
2,022 patients with acute coronary syndrome undergoing percutaneous coronary intervention, followed for 30 days.
I
Intervention
Abciximab administered during a PCI procedure
C
Comparator
Placebo administered during a PCI procedure
O
Outcome
Incidence of major adverse cardiac events (MACE) during the 30 days after PCIcomposite
The efficacy of abciximab in NSTE-ACS patients undergoing PCI is age-dependent, offering significant MACE reduction in patients under 70 but no benefit in older patients.
Cite This Study
Ndrepepa et al. (2006) conducted an RCT in Acute coronary syndrome (n=2,022). Abciximab vs. Placebo was evaluated on Major adverse cardiac events (MACE) during the 30 days after PCI. Abciximab reduced 30-day MACE in patients <70 years old (7.7% vs 13.3%; RR 0.57, 95% CI 0.40-0.80) but not in those ≥70 years old (P=0.04 for interaction).